Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Basis of Cannabis Exposure Risk and Consequences
NCT06058702Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, randomised trial of dronabinol (3 arms), sponsored by Yale University. Primary endpoints: Visual Analog Scale at 360 months, Positive and Negative Symptom Scale at 360 months and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
dronabinol
Beyond the preview
Go deeper on NCT06058702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058702.